Clinical development of a once-daily gastroretentive formulation of gabapentin for treatment of postherpetic neuralgia: an overview

Bibliography

• Mao J, Chen LL. Gabapentin in pain management. Anesth Analg 2000;91(3):680–7
   PubMed Web of Science ®Google Scholar
• Gee NS, Brown JP, Dissanayake VU, The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996;271(10):5768–76
   PubMed Web of Science ®Google Scholar
• Hendrich J, Van Minh AT, Heblich F, Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc Natl Acad Sci USA 2008;105(9):3628–33
   PubMed Web of Science ®Google Scholar
• Attal N, Cruccu G, Haanpaa M, EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006;13(11):1153–69
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O'Connor AB, Audette J, Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85(3 Suppl):S3–14
   PubMed Web of Science ®Google Scholar
• Rice AS, Maton S. Gabapentin in posterpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001;94(2):215–24
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23(8):1296–310
   PubMed Web of Science ®Google Scholar
• Eisen SA, Miller DK, Woodward RS, The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150(9):1881–4
   PubMed Web of Science ®Google Scholar
• Johnson P, Becker L, Halpern R, Use of opioid analgesics in patients with postherpetic neuralgia (PHN) first treated with gabapentin or pregabalin (Abstract presented at American Pain Society (APS), 31st Annual Scientific Meeting, May 16-19, 2012, Honolulu, HI.). J Pain 2012;13(4 Suppl):S70
   Google Scholar
• Bockbrader HN. Clinical Pharmacokinetics of Gabapentin. Drugs of Today 1995;31(No. 8):613–19
   Google Scholar
• Kriel RL, Birnbaum AK, Cloyd JC, Failure of absorption of gabapentin after rectal administration. Epilepsia 1997;38(11):1242–4
   PubMed Web of Science ®Google Scholar
• Stewart BH, Kugler AR, Thompson PR, A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 1993;10(2):276–81
   PubMed Web of Science ®Google Scholar
• Dave MH, Schulz N, Zecevic M, Expression of heteromeric amino acid transporters along the murine intestine. J Physiol 2004;558(Pt 2):597–610
   PubMed Web of Science ®Google Scholar
• Mason GR, Kahrilas PJ, Otterson MF, The Digestive System, in The Digestive System. In: O'Leary JP, editor. The Physiologic Basis of Surgery. Willams and Wilkens; Baltimore: 1996. p. 406–40
   Google Scholar
• Mochiki E, Kuwano H, Nakabayashi T, Pyloric relaxation regulated via intramural neural pathway of the antrum. Dig Dis Sci 2001;46(11):2307–13
   PubMed Web of Science ®Google Scholar
• Sarna SK, Otterson MR, Cowles VE, Telfor GL. Investigations of myogenic, neural and chemical control of small intestinal motor activity. In: Gregersen H, Jensen SL, Moody F, editors. Essentials of experimental surgery. Harwood Academic Publishers; Reading England: 1996. p. 39/1–39/21
   Google Scholar
• Cowles VE, Nellans HN, Seifert TR, Effect of novel motilide ABT-229 versus erythromycin and cisapride on gastric emptying in dogs. J Pharmacol Exp Ther 2000;293(3):1106–11
   PubMed Web of Science ®Google Scholar
• Meyer JH. Motility of the stomach and gastroduocenal junction. In: Johnson LR, editor. Physiology of the gastrointestinal tract. Raven Press; New York, NY, USA: 1987. p. 613–29
   Google Scholar
• Houghton LA, Read NW, Heddle R, Relationship of the motor activity of the antrum, pylorus, and duodenum to gastric emptying of a solid-liquid mixed meal. Gastroenterology 1988;94(6):1285–91
   PubMed Web of Science ®Google Scholar
• Munk JF, Gannaway RM, Hoare M, Johnson AG. Direct measurement of pyloric diameter and tone in man and its response to cholecystokinin. In: Duthie HL, editor. Gastrointestinal motility in health and disease. MTP; Lancaster: 1978. p. 349–59
   Google Scholar
• Timmermans J, Moes AJ. The cutoff size for gastric emptying of dosage forms. J Pharm Sci 1993;82(8):854
   PubMed Web of Science ®Google Scholar
• Timmermans J, Moes AJ. Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: new data for reconsidering the controversy. J Pharm Sci 1994;83(1):18–24
   PubMed Web of Science ®Google Scholar
• Cowles VE, Gusler G, Chen TF, Gastric emptying and intestinal transit of gastroretentive tablets in the fed state: effect of meal content and tablet size. Gastroenterology 2004;126(Suppl 2):A489–90
   Google Scholar
• Hou SYE, Cowles VE, Berner B. Gastric retentive dosage forms: a review. Crit Rev Ther Drug Carrier Syst 2003;20(6):459–97
   PubMed Web of Science ®Google Scholar
• Hwang SJ, Park H, Park K. Gastric retentive drug-delivery systems. Crit Rev Ther Drug Carrier Syst 1998;15(3):243–84
   PubMed Web of Science ®Google Scholar
• Moes AJ. Gastroretentive dosage forms. Crit Rev Ther Drug Carrier Syst 1993;10(2):143–95
   PubMed Web of Science ®Google Scholar
• Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release 2000;63(3):235–59
   PubMed Web of Science ®Google Scholar
• Gusler G, Hou SYE, Connor AL, Pharmacoscintigraphic evaluation of metformin ER in healthy volunteers. Pharm Sci 2003;5:S1
   Google Scholar
• Chen C, Cowles VE, Hou E. Pharmacokinetics of gabapentin in a novel gastric-retentive extended-release formulation: comparison with an immediate-release formulation and effect of dose escalation and food. J Clin Pharmacol 2011;51(3):346–58
   PubMed Web of Science ®Google Scholar
• Gordi T, Hou E, Sreeneeranj K, Berner B. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive- extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects. Clin Ther 2008;30(5):909–16
   PubMed Web of Science ®Google Scholar
• Irving G, Jensen M, Cramer M, Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial. Clin J Pain 2009;25(3):185–92
   PubMed Web of Science ®Google Scholar
• Sang CN, Sathyanarayana R, Sweeney M. Once-daily gabapentin for the treatment of postherpetic neuralgia: results of a multicenter, randomized, double-blind, placebo controlled phase 3 study. Clin J Pain 2012; in press
   Google Scholar
• Wallace MS, Irving G, Cowles VE. Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicentre study. Clin Drug Investig 2010;30(11):765–76
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Corbin AE, Young JP Jr, Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003;60(8):1274–83
   PubMed Web of Science ®Google Scholar
• Sabatowski R, Gálvez R, Cherry DA, Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 2004;109(1-2):26–35
   PubMed Web of Science ®Google Scholar
• van Seventer R, Feister HA, Young JP Jr, Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin 2006;22(2):375–84
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Johnson GR, Shingles prevention study group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271–84
   PubMed Web of Science ®Google Scholar
• Odrcich M, Bailey JM, Cahill CM, Gilron I. Chronobiological characteristics of painful diabetic neuropathy and postherpetic neuralgia: diurnal pain variation and effects of analgesic therapy. Pain 2006;120(1-2):207–12
   PubMed Web of Science ®Google Scholar
• Rowbotham M, Harden N, Stacey B, Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998;280(21):1837–42
   PubMed Web of Science ®Google Scholar
• Irving G. The placebo response: relationship to outcomes in trials of postherpetic neuralgia. Clin Drug Investig 2010;30(11):739–48
   PubMed Web of Science ®Google Scholar
• Quessy SN, Rowbotham MC. Placebo response in neuropathic pain trials. Pain 2008;138(3):479–83
   PubMed Web of Science ®Google Scholar